Table 3.
Annotated plasma metabolites that were differentially expressed (all three p-values ≤0⋅05) at higher or lower levels in Child Pugh B (CP B) vs. Child Pugh A (CP A) HCC patients after one to two fractions of liver SBRT. The p-values presented are from the Wilcoxon rank sum test. Metabolites with all three p-values ≤0⋅05 and q-value ≤0⋅1 are marked ‡. Metabolites identified by GC/MS are marked #, while those identified by LC/MS are not marked.
| AFTER 1 TO 2 FRACTIONS OF SBRT | |||||||
|---|---|---|---|---|---|---|---|
| High expressing metabolites in CP B vs. CP A |
Low expressing metabolites in CP B vs. CP A |
||||||
| Identity† | Fold diff* | p-value | q-value | Identity† | Fold diff* | p-value | q-value |
| C14:1-OH | 1⋅20 | 0⋅021 | 0⋅42 | LysoPC a C26:1 | 0⋅52 | 0⋅001 | 0⋅090‡ |
| C14:2-OH | 1⋅55 | 0⋅012 | 0⋅24 | Uracil# | 0⋅61 | 0⋅003 | 0⋅12 |
| C16:1 | 1⋅39 | 0⋅032 | 0⋅43 | ||||
| C16:1-OH | 1⋅29 | 0⋅022 | 0⋅42 | ||||
| C5:1-DC | 1⋅39 | 0⋅008 | 0⋅27 | ||||
| Citrulline# | 1⋅96 | 0⋅0004 | 0⋅081‡ | ||||
| Glycolic acid# | 1⋅17 | 0⋅046 | 0⋅53 | ||||
| Myo-inositol# | 1⋅66 | 0⋅030 | 0⋅43 | ||||
| Nicotinic acid# | 3⋅07 | 0⋅022 | 0⋅33 | ||||
| N-methyl-glutamic acid 1# | 1⋅25 | 0⋅049 | 0⋅54 | ||||
| PC aa C30:0 | 1⋅68 | 0⋅0005 | 0⋅081‡ | ||||
| PC aa C32:0 | 1⋅64 | 4⋅98E-05 | 0⋅004‡ | ||||
| PC aa C34:1 | 1⋅33 | 0⋅009 | 0⋅32 | ||||
| PC aa C36:1 | 1⋅32 | 0⋅003 | 0⋅15 | ||||
| PC aa C40:2 | 1⋅26 | 0⋅002 | 0⋅12 | ||||
| PC aa C42:0 | 1⋅25 | 0⋅003 | 0⋅15 | ||||
| PC aa C42:4 | 1⋅20 | 0⋅006 | 0⋅17 | ||||
| PC ae C30:0 | 1⋅53 | 0⋅0002 | 0⋅076‡ | ||||
| PC ae C32:1 | 1⋅59 | 1⋅82E-05 | <0⋅001‡ | ||||
| PC ae C32:2 | 1⋅38 | 0⋅0006 | 0⋅084‡ | ||||
| PC ae C34:0 | 1⋅55 | 0⋅001 | 0⋅092‡ | ||||
| PC ae C34:1 | 1⋅58 | 0⋅0002 | 0⋅004‡ | ||||
| PC ae C34:2 | 1⋅49 | 0⋅0005 | 0⋅081‡ | ||||
| PC ae C34:3 | 1⋅52 | 0⋅0003 | 0⋅076‡ | ||||
| PC ae C36:0 | 1⋅51 | 0⋅001 | 0⋅092‡ | ||||
| PC ae C36:2 | 1⋅27 | 0⋅005 | 0⋅19 | ||||
| PC ae C36:3 | 1⋅34 | 0⋅002 | 0⋅12 | ||||
| PC ae C36:4 | 1⋅27 | 0.011 | 0⋅36 | ||||
| PC ae C38:2 | 1⋅18 | 0⋅004 | 0⋅20 | ||||
| PC ae C38:5 | 1⋅45 | 0⋅002 | 0⋅086‡ | ||||
| PC ae C40:5 | 1⋅34 | 0⋅005 | 0⋅12 | ||||
| PC ae C42:2 | 1⋅20 | 0⋅007 | 0⋅27 | ||||
| PC ae C42:3 | 1⋅44 | 0⋅001 | 0⋅092‡ | ||||
| PC ae C42:4 | 1⋅34 | 0⋅001 | 0⋅081‡ | ||||
| PC ae C42:5 | 1⋅31 | 0⋅003 | 0⋅092‡ | ||||
| PC ae C44:3 | 1⋅17 | 0⋅006 | 0⋅25 | ||||
| PC ae C44:5 | 1⋅30 | 0⋅006 | 0⋅24 | ||||
| PC ae C44:6 | 1⋅43 | 0⋅007 | 0⋅27 | ||||
| SM (OH) C24:1 | 1⋅36 | 0⋅011 | 0⋅34 | ||||
| SM C16:0 | 1⋅27 | 0⋅001 | 0⋅081‡ | ||||
| SM C24:1 | 1⋅15 | 0⋅012 | 0⋅36 | ||||
| SM C26:1 | 1⋅33 | 0⋅001 | 0⋅092‡ | ||||
| Taurine | 1⋅50 | 0⋅008 | 0⋅23 | ||||
| Tyrosine | 1⋅52 | 0⋅010 | 0⋅37 | ||||
Fold diff, fold difference between CP B vs. CP A HCC patients.
C14:1-OH, hydroxytetradecenoylcarnitine; C14:2-OH, hydroxytetradecadienylcarnitine; C16:1, hexadecenoylcarnitine; C16:1-OH, hydroxyhexadecenoylcarnitine; C5:1-DC, glutaconylcarnitine; LysoPC a, lysophosphatidylcholine acyl, PC aa, phosphatidylcholine diacyl, PC ae, phosphatidylcholine acyl-alkyl; SM, sphingomyelin.
Metabolites with all three p-values ≤0⋅05 and q-value <0⋅1.
Metabolites identified by GC/MS. Metabolites identified by LC/MS are not marked.